SOX30-mediated activation of CXCL2 as promotor of PMN-MDSC recruitment and immunosuppressive microenvironment in TNBC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results